| Bronchiectasis is one of intractable diseases respiratory system, the key to the pathogenesis of bronchiectasis secondary to bronchial infection and bronchial obstruction, the two influence each other, creating a vicious cycle. Most experts believe that Chinese medicine in stable bronchiectasis etiology and pathogenesis of the wind, phlegm, heat, poison, virtual-based, virtual main qi deficiency based. Study stable bronchiectasis patients with long-term low-dose oral macrolide antibiotics cause everyone’s attention, found that long-term low-dose macrolide antibiotic maintenance therapy can significantly reduce the number of acute exacerbations. Aspects of traditional Chinese medicine in the overall regulation of the body to improve the situation, improve the immune system has certain advantages, but relatively few studies to reduce the frequency of acute exacerbation of stable, strengthen the research of Chinese medicine in treating stable bronchiectasis, reducing stable bronchiectasis patients with acute exacerbations is an important research topic.Clinical found Chaiqianlianmei Decoction treatment falling cough, cough spit green phlegm disease syndrome, the effect is very good, and stable bronchiectasis patients with recurrent cough cough spit green phlegm with the course of time, cough spit green phlegm disease syndrome are very similar. Based on the "fire and vigor not coexistence, a win is a negative" theory, according to the same time stable bronchiectasis of the lung and spleen qi deficiency and phlegm heat in the lung basic pathogenesis. established Buzhong Chaiqianlianmei Decoction, from fill the vitality, purge Yin, phlegm heat treatment of stable bronchiectasis in order to reduce the number of exacerbations. Therefore, we carried out a preliminary study on the stability of Buzhong Chaiqianlianmei Decoction bronchiectasis exacerbations affected, provide the basis for medical treatment in stable bronchiectasis.Objective:To investigate the effect of Buzhong Chaiqianlianmei Decoction on the stability of bronchiectasis exacerbations, and provide the basis for medical treatment in stable bronchiectasis.Methods:A randomized controlled clinical trial design, and 70 patients with stable without hemoptysis were randomly divided into experimental and control groups were given Buzhong Chaiqianlianmei Decoction and azithromycin tablets for 12 weeks, followed up for 12 weeks. Using primary efficacy endpoint (exacerbations, symptom scores, lung function) and secondary efficacy variables (serum immunoglobulins, IL6, mMRC score, FACED score) were evaluated analysis.Result:1 acute exacerbationsTwo groups of patients with acute exacerbation was no significant difference (P> 0.05) between the number of times each observation point group. In the test group, the treatment of acute exacerbations during the 12 weeks was 0.49 times/person, the control group was 0.50 times/person; 12 weeks of follow-up of acute exacerbations in the test group was 0.48 times/person, the control group was 0.53 times/person. Two each observation time point of acute exacerbation was no significant difference (P> 0.05) between the frequency groups.2 Symptom scoreTest total effective rate was 93.94% in the control group, the total effective rate was 93.75%, no significant difference (P> 0.05) effect between two groups, at 0 weeks,3 weeks,6 weeks and 9 weeks of symptoms There was no significant difference (P> 0.05) between the scores Found group,12-week treatment group symptom score was significantly less than the control group (P<0.05).Symptom score before and after the two groups have a relatively significant difference (P<0.01), two groups of cough, sputum, chest tightness, shortness of breath, fatigue, poor appetite, spontaneous no significant difference (P bloating symptoms and pale yellow,> 0.05).3 Pulmonary FunctionAfter treatment, VC, FEV1 percentage among groups was no significant difference (P> 0.05), FEV1/FVC percentages between groups was statistically significant difference (P<0.05), in which the FEV1/FVC percentage of the test group was 74.30±11.046 the control group was 61.40±14.377. There was no significant difference (P> 0.05) in the two groups of patients before and after pulmonary function group.4 FACED score and score mMRCThere was no significant difference (P> 0.05) between the two groups of patients FACED score and score mMRC After treatment, there are two groups of patients before and after within mMRC score group statistically significant difference (P <0.01), FACED score was no significant difference (P> 0.05).5 immunoglobulin and IL6Comparison between immunoglobulin and IL6 no single set of indicators After treatment significant difference (P> 0.05), the two groups showed no significant difference between immunoglobulin (P> 0.05) before and after IL6 within the group.Conclusion:1 Buzhong Chaiqianlianmei Decoction can significantly reduce the stability of bronchiectasis exacerbations.2 Buzhong Chaiqianlianmei Decoction can reduce the stability of bronchiectasis patients with dyspnea severity, and significantly reduce the clinical symptoms of stable bronchiectasis patients. |
PDF Full Text Request